



PRIMARY CONTACTS

- Pierre Etienne, M.D., CEO
petienne@targanta.com
- Thomas Parr, Ph.D., CSO
trparr@targanta.com
- Christian Bélisle, C.A., VP Finance
cbelisle@targanta.com

ADDRESS

Targanta Therapeutics
225 South East Street
Indianapolis, IN 46202-4002

WEBSITE

www.targanta.com

SENIOR MANAGEMENT

- Pierre Etienne, M.D.
President and CEO
- Thomas Parr, Ph.D.
Chief Scientific Officer
- Margaret Wasilewski, M.D.
VP, Clinical Development
- Roger Miller, MS, MBA
VP, Manufacturing
- Christian Bélisle, C.A.
VP, Finance
- William Vladuchick, Ph.D.
VP, Strategic Development
- Gayle Crick Fischer, RPh, MBA
VP, Marketing

FINANCIAL INFORMATION

Targanta has raised to date \$32 million in venture capital and debt funding. Investors include Seaflower Ventures, VenGrowth Private Equity Partners, Fairway Capital Management, and T²C². Targanta plans to raise \$40+ million in mezzanine financing during 2006.

COMPANY PROFILE

Targanta Therapeutics is a privately held biopharmaceutical company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Its pipeline includes an array of antibacterial agents in various stages of development.

The company is headquartered in Indianapolis, Indiana and maintains research and development operations in St. Laurent, Quebec.

PRODUCTS IN DEVELOPMENT

Targanta's lead product, oritavancin, a semi-synthetic glycopeptide antibiotic with bactericidal activity against clinically relevant serious Gram-positive bacterial infections, has completed two Phase III clinical trials. Targanta intends to file an NDA for oritavancin in 2007 for the treatment of complicated skin and skin structure infections.

Targanta's research and development pipeline includes novel antibiotics for the treatment of bacterial bone infections (osteomyelitis) and several small molecules that disrupt bacterial nucleic acid metabolism, all of which originate from the company's in-house chemistry-driven antibiotic discovery program.

BOARD OF DIRECTORS

- Alex Moot, Chairman - *Seaflower Ventures*
- Pierre Etienne, M.D. - *Targanta Therapeutics*
- Michael Cross - *Fairway Capital Management*
- Jeff Courtney - *VenGrowth Private Equity Partners*
- Robin Steele, Esq. - *InterMune, Inc.*
- William Crouse (Independent) - *former General Partner, HealthCare Ventures, former President, Ortho Diagnostics, and VP, Johnson & Johnson*
- Dilip Mehta, M.D., Ph.D. (Independent) - *former SVP, U.S. Clinical Research, Pfizer, Inc.*